These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
404 related articles for article (PubMed ID: 25170258)
1. Two decades of subcutaneous glatiramer acetate injection: current role of the standard dose, and new high-dose low-frequency glatiramer acetate in relapsing-remitting multiple sclerosis treatment. Caporro M; Disanto G; Gobbi C; Zecca C Patient Prefer Adherence; 2014; 8():1123-34. PubMed ID: 25170258 [TBL] [Abstract][Full Text] [Related]
2. Glatiramer Acetate 40 mg/mL in Relapsing-Remitting Multiple Sclerosis: A Review. McKeage K CNS Drugs; 2015 May; 29(5):425-32. PubMed ID: 25906331 [TBL] [Abstract][Full Text] [Related]
3. Glatiramer acetate: a review of its use in patients with relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis. Scott LJ CNS Drugs; 2013 Nov; 27(11):971-88. PubMed ID: 24129744 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing-remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-Frequency Administration open-label extension study. Khan O; Rieckmann P; Boyko A; Selmaj K; Ashtamker N; Davis MD; Kolodny S; Zivadinov R Mult Scler; 2017 May; 23(6):818-829. PubMed ID: 27503905 [TBL] [Abstract][Full Text] [Related]
5. Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis. Carter NJ; Keating GM Drugs; 2010 Aug; 70(12):1545-77. PubMed ID: 20687620 [TBL] [Abstract][Full Text] [Related]
6. Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala study. Sánchez-de la Rosa R; García-Bujalance L; Meca-Lallana J Health Econ Rev; 2015 Dec; 5(1):30. PubMed ID: 26475277 [TBL] [Abstract][Full Text] [Related]
7. Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis. Simpson D; Noble S; Perry C CNS Drugs; 2002; 16(12):825-50. PubMed ID: 12421116 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial. Cree BAC; Goldman MD; Corboy JR; Singer BA; Fox EJ; Arnold DL; Ford C; Weinstock-Guttman B; Bar-Or A; Mientus S; Sienkiewicz D; Zhang Y; Karan R; Tenenbaum N; JAMA Neurol; 2020 Aug; 78(1):1-13. PubMed ID: 32852530 [TBL] [Abstract][Full Text] [Related]
9. Spotlight on glatiramer acetate in relapsing-remitting multiple sclerosis. Simpson D; Noble S; Perry C BioDrugs; 2003; 17(3):207-10. PubMed ID: 12749757 [TBL] [Abstract][Full Text] [Related]
10. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Mikol DD; Barkhof F; Chang P; Coyle PK; Jeffery DR; Schwid SR; Stubinski B; Uitdehaag B; Lancet Neurol; 2008 Oct; 7(10):903-14. PubMed ID: 18789766 [TBL] [Abstract][Full Text] [Related]
11. Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study. Filippi M; Wolinsky JS; Comi G; Lancet Neurol; 2006 Mar; 5(3):213-20. PubMed ID: 16488376 [TBL] [Abstract][Full Text] [Related]
12. First-line disease-modifying therapies in paediatric multiple sclerosis: a comprehensive overview. Johnston J; So TY Drugs; 2012 Jun; 72(9):1195-211. PubMed ID: 22642799 [TBL] [Abstract][Full Text] [Related]
14. [Efficacy, safety and tolerability of glatiramer acetate injections in dose 40 mg/ml in patients with relapsing-remitting multiple sclerosis]. Boyko AN; Alifirova VM Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(11):135-139. PubMed ID: 29265099 [TBL] [Abstract][Full Text] [Related]
15. Glatiramer acetate: long-term safety and efficacy in relapsing-remitting multiple sclerosis. Boster AL; Ford CC; Neudorfer O; Gilgun-Sherki Y Expert Rev Neurother; 2015 Jun; 15(6):575-86. PubMed ID: 25924547 [TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States. Hernandez L; Guo S; Kinter E; Fay M J Med Econ; 2016 Jul; 19(7):684-95. PubMed ID: 26947984 [TBL] [Abstract][Full Text] [Related]
17. What is new in the treatment of multiple sclerosis? Weinstock-Guttman B; Jacobs LD Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827 [TBL] [Abstract][Full Text] [Related]
18. A randomized controlled double-masked trial of albuterol add-on therapy in patients with multiple sclerosis. Khoury SJ; Healy BC; Kivisäkk P; Viglietta V; Egorova S; Guttmann CR; Wedgwood JF; Hafler DA; Weiner HL; Buckle G; Cook S; Reddy S Arch Neurol; 2010 Sep; 67(9):1055-61. PubMed ID: 20837847 [TBL] [Abstract][Full Text] [Related]
19. New FDA-Approved Disease-Modifying Therapies for Multiple Sclerosis. English C; Aloi JJ Clin Ther; 2015 Apr; 37(4):691-715. PubMed ID: 25846320 [TBL] [Abstract][Full Text] [Related]
20. GLACIER: An open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40 mg three-times weekly versus 20 mg daily in patients with relapsing-remitting multiple sclerosis. Wolinsky JS; Borresen TE; Dietrich DW; Wynn D; Sidi Y; Steinerman JR; Knappertz V; Kolodny S; Mult Scler Relat Disord; 2015 Jul; 4(4):370-6. PubMed ID: 26195058 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]